GenSight Biologics Reports Full Year 2016 Financial Results
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced its full year 2016 financial results. Selected financial information (IFRS) In million euros 2015 2016 Operating income 3.6 3.0 Research and development expenses (10.7) (18.5) General and ad